Efficacy of tiotropium–olodaterol fixed-dose combination in COPD

Efficacy of tiotropium–olodaterol fixed-dose combination in COPD

Eric Derom, Guy G Brusselle, Guy F Joos Department of Respiratory Medicine, Ghent University Hospital, Ghent, BelgiumAbstract: Tiotropium–olodaterol, formulated in the Respimat soft-mist inhaler, is an inhaled fixed-dose combination (FDC) of a long-acting muscarinic antagonist (LAMA) and a...

Full description

Bibliographic Details
Main Authors:	Derom E, Brusselle GG, Joos GF
Format:	Article
Language:	English
Published:	Dove Medical Press 2016-12-01
Series:	International Journal of COPD
Subjects:	COPD bronchodilatation dyspnea exacerbation exercise tolerance LABA LAMA spirometry
Online Access:	https://www.dovepress.com/efficacy-of-tiotropiumndasholodaterol-fixed-dose-combination-in-copd-peer-reviewed-article-COPD

Similar Items

Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities
by: Kalhan R, et al.
Published: (2021-04-01)

Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis
by: Vogelmeier C, et al.
Published: (2016-12-01)

A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management
by: Micheletto C, et al.
Published: (2019-09-01)

Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD
by: Chen R, et al.
Published: (2020-01-01)

A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT® Study Protocol
by: Buhl R, et al.
Published: (2020-10-01)

Elderly age group patients with COPD continuing to smoke -a problem that cannot be ignored
by: Vitalii I. Kupaev, et al.
Published: (2020-06-01)

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
by: Rodrigo GJ, et al.
Published: (2017-03-01)

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review
by: Rogliani P, et al.
Published: (2018-10-01)

Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England
by: Requena G, et al.
Published: (2023-07-01)

An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD
by: Singh D, et al.
Published: (2019-12-01)

Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist
by: Yang HH, et al.
Published: (2017-08-01)

Day and Night Control of COPD and Role of Pharmacotherapy: A Review
by: Braghiroli A, et al.
Published: (2020-06-01)

Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study
by: Hsieh MJ, et al.
Published: (2022-04-01)

Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan
by: Yamada H, et al.
Published: (2018-10-01)

The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects
by: Eric Derom, et al.
Published: (2019-04-01)

LA inhalers for COPD: perceptions/reality of ABCD GOLD tool use
by: Varvara Boryushkina, et al.
Published: (2020-07-01)

LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations
by: Marc Miravitlles, et al.
Published: (2022-11-01)

Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results
by: Hoogendoorn M, et al.
Published: (2019-02-01)

Real-world effectiveness of early intervention with fixed-dose tiotropium/olodaterol vs tiotropium in Japanese patients with COPD: a high-dimensional propensity score–matched cohort analysis
by: Shigeo Muro, et al.
Published: (2021-06-01)

Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study
by: Ichinose M, et al.
Published: (2018-07-01)

Roflumilast: the fourth Mousquetaire in COPD pharmacological treatment
by: Bruno Balbi
Published: (2015-08-01)

Early COPD diagnosis and treatment: A case report
by: Roberto G. Carbone, et al.
Published: (2023-01-01)

Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD
by: Bourbeau J, et al.
Published: (2021-03-01)

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
by: Nicola C. Day, et al.
Published: (2020-06-01)

Comparative efficacy and safety of glycopyrronium/formoterol fixed-dose combination versus glycopyrronium monotherapy in patients with moderate-to–severe COPD
by: Sundeep Salvi, et al.
Published: (2022-01-01)

Cost-Effectiveness Analysis of Fixed-Dose Tiotropium/Olodaterol versus Tiotropium for COPD Patients in China
by: Lan Y, et al.
Published: (2023-09-01)

The Role of Dual Bronchodilation and the Conscientious Use of Inhaled Corticosteroid in COPD
by: Ricardo G. Figueiredo, et al.
Published: (2022-08-01)

The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease (COPD) in an Italian Context of Real Life: The TRITRIAL Study Protocol
by: Richeldi L, et al.
Published: (2021-01-01)

GOLD in Practice: Chronic Obstructive Pulmonary Disease Treatment and Management in the Primary Care Setting
by: Yawn BP, et al.
Published: (2021-02-01)

Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating Patients with COPD Receiving Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy
by: Moretz C, et al.
Published: (2020-09-01)

Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study
by: Moretz C, et al.
Published: (2019-08-01)

Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD
by: Chan M, et al.
Published: (2018-04-01)

A comparison of tiotropium, long-acting β2-agonists and leukotriene receptor antagonists on lung function and exacerbations in paediatric patients with asthma
by: Christian Vogelberg, et al.
Published: (2020-01-01)

Exercise capacity and physical activity in COPD patients treated with a LAMA/LABA combination: a systematic review and meta-analysis
by: Marc Miravitlles, et al.
Published: (2022-12-01)

New pharmacological options in the chronic obstructive pulmonary disease
by: Surama Martínez Chávez, et al.
Published: (2016-07-01)

Validity of COPD diagnoses reported through nationwide health insurance systems in the People’s Republic of China
by: Kurmi OP, et al.
Published: (2016-03-01)

Disease Trajectories and Impact of One Moderate Exacerbation in Gold B COPD Patients
by: Løkke A, et al.
Published: (2022-03-01)

Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol
by: Dave Singh, et al.
Published: (2017-05-01)

The Effectiveness of 3 Combined Therapeutic Regimens in Egyptian Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: A Randomized Double-Blind Prospective Pilot Study
by: Tarek M. Mostafa, et al.
Published: (2021-01-01)

AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD
by: Sethi S, et al.
Published: (2019-03-01)